INHIBITION OF ASCORBIC-ACID-INDUCED
DEPOLYMERIZATION OF HYALURONIC ACID BY
CERULOPLASMIN IN SYNOVIAL FLUID*

BY
WILLIAM NIEDERMEIER

From the Division of Rheumatic Diseases, Department of Medicine, The Medical Center,
University of Alabama, Birmingham, Ala

It has been demonstrated in vitro that low concentrations of ascorbic acid rapidly depolymerize purified hyaluronic acid as judged from viscosity measurements (Skanse and Sundblad, 1943; Pigman, Rizvi, and Holley, 1961). Abrams and Sandson (1964) reported that the hyaluronic acid in rheumatoid synovial fluid is resistant to depolymerization by ascorbic acid in vitro. Serum proteins have been shown to inhibit the action of ascorbic acid on purified hyaluronic acid. The alpha-2 globulin fraction was found to contain the serum proteins most active in inhibiting the reaction (De Salegui, Rizvi, Holley, and Pigman, 1962; Pigman and Rizvi, 1959). The increased concentration of blood serum proteins in synovial fluid from patients with rheumatoid arthritis has been repeatedly reported since the original observation of Ropes and Bauer (1953), and the marked increase in alpha-2 globulins has been noted by Binette and Schmid (1965). Reports from this laboratory showed that the concentrations of haptoglobin (Niedermeier, Cross, and Beetham, 1965) and ceruloplasmin (Niedermeier, 1965a), which are both alpha-2 glycoproteins, are markedly raised in synovial fluid of patients with rheumatoid arthritis. Ceruloplasmin has been shown to inhibit ascorbic acid-induced depolymerization of purified preparations of hyaluronic acid (Niedermeier, 1965b, 1966).

The present studies were undertaken to determine whether the presence of ceruloplasmin in increased amounts could account for the failure of ascorbic acid to depolymerize hyaluronic acid in synovial fluid from patients with rheumatoid arthritis.

Material and Methods

Material.—Purified hyaluronic acid that contained less than 4 per cent. protein was prepared from cattle synovial fluid by the cetylpyridinium chloride precipitation method (Matsumura, De Salegui, Herp, and Pigman, 1963). The preparation used in these studies had a hyaluronic acid concentration of 207 mg./100 ml. and an intrinsic viscosity of 46 dl./g.

Synovial fluid specimens were collected from the knee joints of seven cadavers, selected at random, without evidence of rheumatic disease and from eight living patients who had definite or classical rheumatoid arthritis (Ropes, Bennett, Cobb, Jacox, and Jessar, 1957). The specimens were stored at 2°C, until used. To some of the specimens from patients with rheumatoid arthritis an equal volume of purified hyaluronic acid was added in order to increase their hyaluronic acid concentration and viscosity to values comparable to those of the post mortem specimens. The analytical values listed in Table II for intrinsic viscosity, hyaluronic acid concentration, and ceruloplasmin concentration of solutions prepared from rheumatoid synovial fluid were obtained after addition of purified hyaluronic acid to the synovial fluids.

Purified ceruloplasmin was supplied by the American National Red Cross and A. B. Kabi, Stockholm. Tiselius electrophoresis in veronal buffer, 0·1 μ at pH 8·6 showed that, in addition to ceruloplasmin which had a mobility of 4·6, all the preparations contained a contaminant with a mobility of 5·50 which probably represented an alpha-1 globulin. Two preparations that contained different proportions of what appeared electrophoretically to be the same contaminant had essentially the same activity per mg. ceruloplasmin in protecting hyaluronic acid from depolymerization by ascorbic acid, indicating that the results obtained represent the activity of ceruloplasmin and not the alpha-1 globulin contaminant. Reagent grade L-ascorbic acid was purchased from J. T. Baker Chemical Company.

Ceruloplasmin concentration was determined on the basis of its capacity to oxidize paraphenylenediamine by the method of Scheinberg and Morell (1957). Total protein was determined by the Phenol method (Lowry, Rosebrough, Farr, and Randall, 1951). Hyaluronic acid was determined by the method of Dische (1947).

Depolymerization as measured by Changes in Specific Viscosity.—All experiments involving the effect of ascorbic acid on viscosity of purified hyaluronic acid were

* Supported by grants from the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Maryland, and Merck Sharp and Dohme, West Point, Pennsylvania.
conducted on solutions that contained 70 mg per cent. hyaluronic acid, 0·08 mM/l. ascorbic acid and 0·2 M phosphate buffer at pH 7·4. After the addition of a freshly-prepared solution of ascorbic acid, which was the last reagent added, a stop-watch was started. The solution was thoroughly mixed and an aliquot placed in a Cannon-Manning semi-micro viscometer maintained at a constant temperature of 30°C. The flow time was recorded within 3 minutes after the addition of ascorbic acid and was repeated at intervals for up to 12 hours. From the flow time of 0·2 M phosphate buffer, in the same viscometer, specific fluidities ($\phi=1/\eta_{sp}$) were calculated and plotted as a function of time. The increase in fluidity was essentially linear during the first 2 hours of reaction. The results were expressed in terms of change in specific fluidity per minute ($\Delta \phi$/min.) during the first 30 minutes of the reaction.

Results

The typical effects of 0·08 mM/l. ascorbic acid on depolymerization of hyaluronic acid in post mortem synovial fluid (PMSF), rheumatoid synovial fluid (RASF), and rheumatoid synovial fluid to which purified hyaluronic acid (RASF + HA) was added are compared with its effect on purified hyaluronic acid (HA) in the Figure. The initial rate of depolymerization of purified hyaluronic acid was considerably greater than that of hyaluronic acid in post mortem synovial fluid. In the presence of rheumatoid synovial fluid, neither endogenously present hyaluronic acid nor purified hyaluronic acid added to the fluid were appreciably depolymerized by 0·08 mM/l. ascorbic acid.

![Graph](image)

Fig. 1.—Effect of 0·08 mM/l. ascorbic acid on the fluidity of human post mortem synovial fluid (PMSF), rheumatoid synovial fluid (RASF), and rheumatoid synovial fluid to which purified hyaluronic acid from cattle synovial fluid was added (RASF + HA), and a solution of purified hyaluronic acid from cattle synovial fluid (HA). All solutions were prepared in 0·2 M phosphate buffer, pH 7·4.

The effect of 0·08 mM/l. ascorbic acid on depolymerization of hyaluronic acid was determined in seven specimens of post mortem synovial fluid and in eight specimens of rheumatoid synovial fluid to which purified hyaluronic acid was added as shown in Table I. The ceruloplasmin and hyaluronic acid concentrations indicated in the Table represent the concentrations in the solutions on which viscosity measurements were made. The mean ceruloplasmin concentration in solutions prepared from seven specimens of post mortem synovial fluid was 1·0 mg per cent. and the mean rate of increase in fluidity was 0·008 $\phi$ units/min. The mean ceruloplasmin concentration in solutions prepared from eight specimens of rheumatoid synovial fluid was 4·3 mg per cent. and the rate of increase in fluidity was less than 0·001 $\phi$ units/min., or more than 87·5 per cent. less than that in those prepared from post mortem synovial fluid.

<table>
<thead>
<tr>
<th>Synovial Fluid</th>
<th>Specimen No.</th>
<th>Hyaluronic Acid mg per cent.</th>
<th>Ceruloplasmin mg per cent.</th>
<th>Fluidity Initial $\Delta \phi$/min.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post mortem</td>
<td>9</td>
<td>42·5</td>
<td>55·5</td>
<td>0·00</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>49·5</td>
<td>71·6</td>
<td>0·145</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>51·5</td>
<td>65·4</td>
<td>0·222</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>47·0</td>
<td>61·4</td>
<td>0·150</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>64·0</td>
<td>50·0</td>
<td>0·212</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>56·0</td>
<td>62·6</td>
<td>0·195</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>64·0</td>
<td>47·3</td>
<td>0·197</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td>0·008</td>
</tr>
</tbody>
</table>
| Patients with Rheumatoid Arthritis | 17 | 63·5 | 5·75 | 0·331 | -0·
|               | 18           | 60·1                       | 4·85                      | 0·351                             |
|               | 19           | 50·1                       | 5·95                      | 0·380                             |
|               | 20           | 65·5                       | 6·40                      | 0·292                             |
|               | 21           | 70·5                       | 5·00                      | 0·311                             |
|               | 22           | 103·5                      | 4·05                      | 0·250                             |
|               | 23           | 104·5                      | 3·00                      | 0·146                             |
|               | 24           | 85·0                       | 3·45                      | 0·216                             |
| Mean          |              |                            |                           | 0·008                             |

*Ascorbic acid concentration—0·8 mM/l. $\eta_{sp}$—Intrinsic viscosity in dl./g.

The capacity of ceruloplasmin to inhibit depolymerization of hyaluronic acid in a purified preparation under the same conditions was approximately proportional to its concentration as shown in Table II (opposite).

In the absence of ceruloplasmin, 0·08 mM/l. ascorbic acid effected an increase in fluidity of the solution of 0·0134 $\phi$ units/min. In the presence of...
CERULOPLASMIN IN SYNOVIAL FLUID

5 mg. per cent. ceruloplasmin, the hyaluronic acid underwent depolymerization at a rate equivalent to 0.0116 \( \phi \) units/min. or 13.6 per cent. less than in the absence of ceruloplasmin. In order to obtain changes in fluidity equivalent to those observed for post mortem and rheumatoid synovial fluid it was necessary to increase the ceruloplasmin concentration to 50 and 100 mg. per cent. respectively.

<table>
<thead>
<tr>
<th>Table II</th>
<th>EFFECT OF CERULOPLASMIN ON ASCORBIC ACID-INDUCED DEPOLYMERIZATION OF PURIFIED HYALURONIC ACID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceruloplasmin Concentration (mg. per cent.)</td>
<td>Fluidity  ( \phi )</td>
</tr>
<tr>
<td>0 (Control)</td>
<td>0.0134</td>
</tr>
<tr>
<td>5</td>
<td>0.0116</td>
</tr>
<tr>
<td>10</td>
<td>0.0096</td>
</tr>
<tr>
<td>50</td>
<td>0.0012</td>
</tr>
<tr>
<td>100</td>
<td>0.0007</td>
</tr>
</tbody>
</table>

*per cent. inhibition = \( \frac{\Delta \phi \text{ Control} - \Delta \phi \text{ in presence of ceruloplasmin}}{\Delta \phi \text{ control}} \times 100 \)

The capacity of blood serum to inhibit depolymerization of purified hyaluronic acid is demonstrated by the data presented in Table IV (overleaf).

Three serum specimens, selected on the basis of their content of ceruloplasmin, from a patient with Wilson's disease, a patient with rheumatoid arthritis, and a "normal" volunteer, contained 5, 76, and 28 mg. per cent. ceruloplasmin respectively. These were added in the quantities indicated in Table IV to solutions of purified hyaluronic acid and their capacity to inhibit ascorbic acid induced depolymerization was determined. The concentrations of total protein and ceruloplasmin indicated in the Table represent the final concentrations in the solution on which viscosities were determined. All three blood serum specimens were potent inhibitors of depolymerization. Their capacity to inhibit the reaction was greatly in excess of that which could be attributed to their ceruloplasmin content. Even the specimen of blood serum from the patient with Wilson's disease, which contributed only minute quantities of ceruloplasmin, was a potent inhibitor. The addition of 0.25 ml. rheumatoid blood serum contributed only 9.5 mg. per cent. ceruloplasmin to the solution. The fluidity of this solution increased at the rate of only 0.0003 \( \phi \) units/min., 97.5 per cent. less than that of the solution in the absence of added blood serum or ceruloplasmin. As noted in Table II, the increase in fluidity of a solution of purified hyaluronic acid in the presence of 10 mg. per cent. ceruloplasmin was 0.0096 \( \phi \) units/min., only 53.8 per cent. less than that in the absence of ceruloplasmin.

When considered on the basis of total protein concentration, however, ceruloplasmin was a more effective inhibitor than whole blood serum. In the presence of 100 mg. per cent. ceruloplasmin, as noted in Table II, the fluidity increased only 0.0007 \( \phi \) units/min., 94.4 per cent. less than the comparable solution which contained no ceruloplasmin. In the presence of 200 mg. per cent. blood serum proteins...
from either the patient with Wilson's disease or the "normal" volunteer, fluidity increased at the rate of 0.0065 units/min., 51 per cent. of that for the comparable solution to which no blood serum proteins were added.

**Discussion**

Abrams and Sandson (1964) reported that hyaluronic acid in rheumatoid synovial fluid was resistant to depolymerization by ascorbic acid and suggested that the factor responsible for inhibition of the reaction was an alpha-2 globulin. The present studies also demonstrated the resistance of hyaluronic acid in rheumatoid synovial fluid to depolymerization by 0.08 mM/l. ascorbic acid. The hyaluronic acid present in post mortem synovial fluid from cadavers without evidence of rheumatic disease underwent depolymerization, but at a slower rate than in solutions that contained purified hyaluronic acid in the absence of synovial fluid. By increasing the ascorbic acid concentration to 0.32 mM/l, depolymerization of hyaluronic acid in rheumatoid synovial fluid could be demonstrated. Purified hyaluronic acid from cattle synovial fluid, when added to rheumatoid synovial fluid, was also resistant to depolymerization. This supported the hypothesis that the failure of ascorbic acid to increase the fluidity of the solution was due to the presence of inhibiting factors rather than to a difference in molecular structure or configuration of hyaluronic acid endogenously present in rheumatoid synovial fluid. The capacity of ceruloplasmin to inhibit depolymerization was approximately the same in post mortem synovial fluid as it was in solutions of purified hyaluronic acid.

The experiments in which the effect of blood serum on the depolymerization of hyaluronic acid by ascorbic acid was studied revealed that, on the basis of total protein concentration, whole blood serum was less effective than ceruloplasmin in inhibiting the reaction. The activity of whole blood serum was greater, however, than could be accounted for on the basis of its ceruloplasmin concentration. The results indicate that blood serum contains some factor in addition to ceruloplasmin that inhibits the depolymerization of hyaluronic acid by ascorbic acid. This factor, which appears to act independently of ceruloplasmin, is probably also present in synovial fluid. Its concentration, like that of serum proteins in general, is probably raised in the synovial fluid of patients with rheumatoid arthritis. There is the possibility that purified ceruloplasmin was less active than that endogenously present in blood serum due to partial denaturation of the glycoprotein during the process of isolation and purification. Small differences in activity of different purified ceruloplasmin preparations were noted.

The observation that hyaluronic acid in synovial fluid of patients with rheumatoid arthritis is depolymerized in the presence of raised concentrations of
CERULOPLASMIN IN SYNOVIAL FLUID

Ceruloplasmin and a second factor which inhibits depolymerization of hyaluronic acid is difficult to explain. It is suggested that, in the joints of these patients, hyaluronic acid is depolymerized by a mechanism other than that involving ascorbic acid, and that the increase in ceruloplasmin concentration is a secondary event which may inhibit further depolymerization by the reaction involving ascorbic acid.

It cannot be precluded that the results of the present study were not influenced by post mortem changes which take place in synovial fluid. Platt, Pigman, Holley, and Patton (1956) noted that the total nitrogen concentration and electrophoretic behaviour of the proteins in post mortem synovial fluid were the same as in normal human synovial fluid. They reported, however, that the NPN value for post mortem fluids was approximately three times that of the normal fluids. Stafford, Niedermeier, Holley, and Pigman (1964) demonstrated that the hyaluronic acid concentration of post mortem synovial fluid is about 40 per cent. less than that of normal volunteers. This difference was attributed to post mortem dilution of the fluid. It was also noted, however, that the intrinsic viscosity of hyaluronic acid in post mortem synovial fluid was essentially the same as that of hyaluronic acid in synovial fluid from normal volunteers.

Niedermeier (1965a) observed that, within the limits of normal variation and experimental error, the concentration of ceruloplasmin was the same in post mortem synovial fluid as in normal human synovial fluid.

Summary and Conclusions

The effect of ceruloplasmin on the ascorbic acid-induced depolymerization of hyaluronic acid as judged from changes in fluidity was studied. Hyaluronic acid in rheumatoid synovial fluid was more resistant to depolymerization by ascorbic acid than that in post mortem synovial fluid. The increased concentration of ceruloplasmin in synovial fluid from patients with rheumatoid arthritis is probably in part responsible for this difference. Other factors appear to be present in blood serum and probably also in synovial fluid which are active in inhibiting ascorbic acid-induced depolymerization of hyaluronic acid.

REFERENCES


---

Inhibition par la ceruloplasmine de la dépolymérisation de l’acide hyaluronique, induite par l’acide ascorbique, dans le liquide synovial

**Résumé**

On étudia l’effet de la ceruloplasmine sur la dépolymérisation de l’acide hyaluronique induite par l’acide ascorbique en fonction des modifications de la fluidité. L’acide hyaluronique du liquide synovial rhumatoïde était plus résistant à la dépolymérisation par l’acide ascorbique que celui du liquide synovial du cadavre. La concentration accrue en ceruloplasmine dans le liquide synovial des malades atteints de polyarthrite rhumatoïde est probablement responsable en partie de cette différence. D’autres facteurs semblent exister dans le sérum sanguin et probablement aussi dans le liquide synovial, qui sont capables d’inhiber la dépolymérisation de l’acide hyaluronique induite par l’acide ascorbique.

---

Inhibición por la ceruloplasmina de la depolimerización del ácido hialurónico, inducida por el ácido ascóbico, en el líquido sinovial

**SUMARIO**

Se estudió el efecto de la ceruloplasmina sobre la depolimerización del ácido hialurónico, inducida por el ácido ascóbico en función de las modificaciones de la fluididad. El ácido hialurónico del líquido sinovial reumatoide fue más resistente a la depolimerización por el ácido ascóbico que el del líquido sinovial recogido post mortem. La concentración aumentada de ceruloplasmina en el líquido sinovial de enfermos con artritis reumatoide se debe probablemente, en parte, a esta diferencia. Otros factores parecen existir en el suero sanguíneo y probablemente también en el líquido sinovial con la capacidad de inhibir la depolimerización del ácido hialurónico inducida por el ácido ascóbico.
Inhibition of ascorbic-acid-induced depolymerization of hyaluronic acid by ceruloplasmin in synovial fluid.
W Niedermeier

Ann Rheum Dis 1968 27: 71-76
doi: 10.1136/ard.27.1.71

Updated information and services can be found at:
http://ard.bmj.com/content/27/1/71.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/